Pyrazine derivatives: A patent review (2008 present)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 9, 2012, Pages 1033-1051

  Ferreira, Sabrina Baptista ^a   Kaiser, Carlos Roland ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Anticancer compounds; Flavors; Pyrazinamide; Pyrazines; Tuberculostatic

Indexed keywords

2 ALKYLENYLOXY 3 ETHYNYLPYRIDO[2,3 B]PYRAZINE DERIVATIVE; 2 N [(3,4,5 TRIMETHOXYPHENYL)METHYLIDENE] 2 PYRAZINECARBOHYDRAZIDE; 2,5 DIMETHYL 3 (2 METHYLBUTYL)PYRAZINE; BARRENAZINE A; BARRENAZINE B; BOTRYLLAZINE A; BOTRYLLAZINE B; CEPHALOSTATIN; IMIDAZOPYRAZINE DERIVATIVE; LUCIFERIN; MIRFENTANIL; PELAGIOMICIN A; PELAGIOMICIN B; PELAGIOMICIN C; PYRAZINAMIDE; PYRAZINAMIDRAZONE DERIVATIVE; PYRAZINE DERIVATIVE; PYRAZINECARBOHYDRAZIDE DERIVATIVE; PYRIDINE DERIVATIVE; RITTERAZINE B; STILBENE DERIVATIVE; TETRAMETHYLPYRAZINE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTINOCICEPTION; ANTIVIRAL ACTIVITY; CEREBROVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; REVIEW; TUBERCULOSIS;

ANIMALS; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84865488388     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.714370     Document Type: Review

References (93)

1. Davidson D, Weiss M, Jelling M. The action of ammonia on benzoin. J Org Chem 1937;2:328-34
2. Muller R, Rappert S. Pyrazines: Occurrence, formation and biodegradation. Appl Microbiol Biotechnol 2010;85:1315-20. The authors conducted a detailed review of the degradation of pyrazines in humans and animals.
3. Wagner R, Czerny M, Bielohradsky J, Grosch W. Structure-odour-activity relationships of alkylpyrazines. Z Lebensm Unters Forsch A 1999;208:308-16
4. Damani LA, Crooks PA. Oxidative metabolism of heterocyclic ring systems. In: Jakoby WB, Bend JR, Caldwell J, editors. Metabolic basis of detoxication. Academic Press; New York: 1992. p. 69-89
5. Schranker LS, Shore PA, Brodie BB, Hogben CAM. Absorption of drugs from the stomach. I. The rat. J Pharmacol Exp Ther 1957;120:528-39
6. Hogben CA, Tocco DJ, Brodie BB, Schanker LS. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 1959;125:275-82
7. Hawksworth G, Scheline RR. Metabolism in the rat of some pyrazine derivatives having flavour importance in foods. Xenobiotica 1975;5:389-99
8. Sjodin P, Wallin H, Alexander J, Jagerstad M. Disposition and metabolism of the food mutagen 2-amino-3,8- dimethylimidazo[4,5-f]quinoxaline (MeIQx) in rats. Carcinogenesis 1989;10:1269-75 (Pubitemid 19177232)
9. Arnoldi A, Arnoldi C, Baldi O, Griffini A. Flavor components in the Maillard reaction of different amino acids with fructose in cocoa butter-water. Qualitative and quantitative analysis of pyrazines. J Agric Food Chem 1988; 36:988-92
10. Sumoto K, Irie M, Mibu N, et al. Formation of pyrazine derivatives from d-glucosamine and their deoxyribonucleic acid (dna) strand breakage activity. Chem Pharm Bull 1991;39:792-4. The authors showed interesting activity of strand breakage of deoxyribonucleic acid (DNA).
11. Rohovec J, Kotek J, Peters JA, Maschmeyer T. A Clean Conversion of D-Glucosamine Hydrochloride to a Pyrazine Derivative in the presence of Phenylboronate or Borate. Eur J Org Chem 2001;3899-901 (Pubitemid 32983151)
12. Kerns RJ, Tpoida T, Linhardt RJ. Synthesis of the Bis-Tetrahydropyrano [2,3-b:2¢,3¢-e] Piperazine Ring System: A New Tricyclic Heterocycle from D-Glucosamine. J Carbohydr Chem 1996;15:581-90
13. Adams A, Kimpe N. Formation of pyrazines from ascorbic acid and amino acids under dry-roasting conditions. Food Chem 2009;115:1417-23
14. Krems IJ, Spoerri PE. The Pyrazines. Chem Rev 1947;40:279-358. The authors reviews the synthesis of pyrazines.
15. Wu G, Yin W, Shen HC, Huang Y. One-pot synthesis of useful heterocycles in medicinal chemistry using a cascade strategy. Green Chem 2012;14:580-5
16. Polshettiwar V, Varma RS. Greener and expeditious synthesis of bioactive heterocycles using microwave irradiation. Pure Appl Chem 2008;80:777-90
17. Goya P, Campillo N, Garcia-Gomez C, et al. Heterocyclic structures useful in medicinal chemistry: The case of pyrazino [2,3-c][1,2,6]thiadiazine 2,2-dioxide. Farmaco 1997;52:283-7 (Pubitemid 27364305)
18. Ferreira SB, Sodero ACR, Cardoso MFC, et al. Synthesis, biological activity, and molecular modeling studies of 1 -1,2,3-triazole derivatives of carbohydrates as alfa-glucosidases inhibitors. J. Med. Chem 2010; 53:2364-75
19. Miralinaghi P, Salimi M, Shirmohammadli S, Amini M. Synthesis and cytotoxicity evaluation of diarylpyrazine and dihydropyrazine derivatives. Int J Pharm Bio Sci 2011;2:60-4
20. Voss ME, Rainka MP, Fleming M, et al. Synthesis and SAR studies of imidazo- [1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity. Bioorg Med Chem Lett 2012;22:3544-9
21. Maga JA. Pyrazine update. Food Rev Inter 1992;8:479-558
22. Shipar AH. Formation of pyrazines in dihydroxyacetone and glycine Maillard reaction: A computational study. Food Chem 2006;98:403-15
23. Van Lancker F, Adams A, De Kimpe N. Impact of the N-terminal amino acid on the formation of pyrazines from peptides in maillard model systems. J Agric Food Chem 2012;6:4697-708
24. Harrison TJ, Dake GR. An expeditious, high-yielding construction of the food aroma compounds 6-acetyl- 1,2,3,4-tetrahydropyridine and 2-acetyl- 1-pyrroline. J Org Chem 2005; 70:10872-4 (Pubitemid 43041100)
25. Grandhee SK, Monnier VM. Mechanism of formation of the maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991;266:11649-53 (Pubitemid 21906998)
26. Guerra PV, Yaylayan VA. Dimerization of azomethine ylides: An alternate route to pyrazine formation in the maillard reaction. J Agric Food Chem 2010;58:12523-9
27. Hwang HI, Hartman TG, Rosen RT, Ho CT. Formation of pyrazines from the Maillard reaction of glucose and g1utamine-amide-15N. J Agric Food Chem 1993;41:2112-15
28. Shu CK. Pyrazine formation from serine and threonine. J Agric Food Chem 1999;47:4332-5
29. Besson I, Creuly C, Gros JB, Larroche C. Pyrazine production by Bacillus subtilis in solid-state fermentation on soybeans. Appl Microbiol Biotechnol 1997;47:489-95 (Pubitemid 27272551)
30. Kim KS, Lee HJ, Shon DH, Chung DK. Optimum conditions for the production of tetramethylpyrazine flavor compound by aerobic fed-batch culture of Lactococcus lactis subsp. lactis biovar diacetylactis FC1. J Microbiol Biotechnol 1994;4:327-32
31. Staledel W, Rugheimer L. Ueber die Einwirkung von Ammoniak auf Chloracetylbenzol. Berichte der Deutschen Chemischen Gesellschaft 1876;9:563-4
32. Krems IJ, Spoerri PE. The pyrazines. Chem Rev 1947;40:279-358
33. Gastaldi G. Pyrazines synthesis. Gazz Chim Ital 1921;51:233-55
34. Lawrence SA. Amines: Synthesis, properties and applications. 1st edition, Cambridge University Press; Cambridge, United Kingdom: 2004, p. 10-15
35. Dickschat JS, Reichenbach H, Wagner-Dobler I, Schulz S. PN3Novel Pyrazines from the Myxobacterium Chondromyces crocatus and Marine Bacteria. Eur J Org Chem 2005;4141-53
36. Xu H, Shi DZ, Guan CY. Pyrazines derivatives. Chin J Integr Tradit. West Med 2003;23:376
37. Bing-Feng Z, Yan X, Wen-Lai F. High-yield fermentative preparation of tetramethylpyrazine by Bacillus sp using an endogenous precursor approach. J Ind Microb Biotechnol 2010;37:179-86
38. Zviely M, Abushqara E, Hodrien D. Chocarom pyrazine: A remarkable pyrazine for flavors and fragrances. Nat Flavors Fragrances ACS Symp Ser 2005;908:189-202
39. Pettit GR, Inoue M, Herald DL, Krupa TS. Isolation and synthesis of the powerful cell growth inhibitor cephalostatin. J Am Chem Soc 1988;110:2006-7 (Pubitemid 18090678)
40. Pettit JR, Xu JP, Schmidt JM. Use of 15N-HMBC NMR techniques to determine the orientation of the steroidal units in ritterazine A. Bioorg Med Chem Lett 1995;5:2027-32
41. Pettit Jr. Marine animal and terrestrial plant anticancer constituents. Pure Appl Chern 1994;66:2271-81
42. Pettit GR, Tan R, Xu J-P, et al. Antineoplastic agents. 398. Isolation and structure elucidation of cephalostatins 18 and 19. J Nat Prod 1998;61:955-98
43. Chill L, Aknin M, Kashman Y. Barrenazine A and B; two new cytotoxic alkaloids from an unidentified tunicate. Org Lett 2003;5:2433-5 (Pubitemid 37140877)
44. Imamura N, Nishijima M, Takadera T, et al. New anticancer antibiotics pelagiomicins, produced by a new marine bacterium Pelagiobacter variabilis. J Antibiot 1997;50:8-12 (Pubitemid 27078052)
45. Duran R, Zubia E, Ortega MJ, et al. Novel alkaloids from the red ascidian botryllus leachi. Tetrahedron 1999; 55:13225-32 (Pubitemid 29502272)
46. Wu C, Kawasaki K, Ohgiya S, Ohmiya Y. Syntheses and evaluation of the bioluminescent activity of (S)- Cypridina luciferin and its analogs. Tetrahedron Lett 2006;47:753-6 (Pubitemid 43014805)
47. Chase AM. The chemistry of cypridina luciferin. Ann NY Acad Sci 1948; 49:353-75
48. Teranishi K. Luminescence of imidazo [1,2-a]pyrazin-3(7H)-one compounds. Bioorg Chem 2007;35:82-111 (Pubitemid 46108994)
49. Showalter DN, Troyer EJ, Aklu M, et al. Alkylpyrazines: Alarm pheromone components of the little fire ant, Wasmannia auropunctata (Roger) (Hymenoptera, Formicidae). Insect Soc 2010;57:223-32
50. Vander Meer RK, Preston CA, Choi MY. Isolation of a pyrazine alarm pheromone component from the fire ant, Solenopsis invicta. J Chem Ecology 2010;36:163-70
51. Dolezal M. Biologicky aktivni pyraziny prirodniho a syntetickeho puvodu. Chem Listy 2006;100:959-66 (Pubitemid 44749399)
52. Lima CHS, Bispo MLF, De Souza MVN. RVQ Pirazinamida: Um farmaco essencial no tratamento da tuberculose. Rev Virtual Quim 2011;3:159-80
53. Shi R, Itagaki N, Sugawara I. Overview of anti-tuberculosis (tb) drugs and their resistance mechanisms. Mini Rev Med Chem 2007;7:1177-85 (Pubitemid 350200224)
54. Judge V, Narasimhan B, Ahuja M. A Review of biological potential of pyrazinamide derivatives. Hygeia J Drugs Med 2012;4:1-6. The author reviews the pharmacological properties of many of the pyrazinamide derivatives.
55. Vergara FMF, Lima CHS, Henriques MGMO, et al. Synthesis and antimycobacterial activity of N'-[(E)- (monosubstitutedbenzylidene)]-2- pyrazinecarbohydrazide derivatives. Eur J Med Chem 2009;44:4954-9
56. Henriques MGMO, Kaiser CR, Lima CHS, De Souza MVN. Synthesis and cytotoxic evaluation of disubstituted n-acylhydrazones pyrazinecarbohydrazide derivatives. Lett Drug Des Discov 2010;7:275-80
57. Lima CHS, Henriques MGMO, Candea ALP, et al. Synthesis and antimycobacterial evaluation of Ń-(E)-heteroaromaticpyrazine-2- carbohydrazide derivatives. Med Chem 2011;7:245-9
58. Foks H, Balewski L, Gobis K, et al. Studies on pyrazine derivatives LII: Antibacterial and antifungal activity of nitrogen heterocyclic compounds obtained by pyrazinamidrazone usage. Heteroatom Chem 2012;23:49-58
59. Dolezal M, Kralova K. Herbicides, theory and applications Chapter 27. In: Soloneski S, Larramendy ML, editors. Synthesis and evaluation of pyrazine derivatives with herbicidal activity. InTech; Rijeka, Croatia: 2011. p. 581-610
60. Dolezal M, Tumova L, Kesetovicova D, et al. Substituted Nphenylpyrazine-2- carboxamides, their synthesis and evaluation as herbicides and abiotic elicitors. Molecules 2007;12:2589-98
61. Kayagil I, Demirayak S. Synthesis of some 2,3,6,8-tetraarylimidazo[1,2-a] pyrazine derivatives by using either reflux or microwave irradiation method, and investigation their anticancer activities. Turk J Chem 2011;3:13-24
62. Deng L, Guo X, Zhai L, et al. Ligustrazine derivatives. Part 4: Design, synthesis, and biological evaluation of novel ligustrazine-based stilbene derivatives as potential cardiovascular agents. Chem Biol Drug Des 2012;79:731-9
63. Da Silva YKC, Augusto CV, Barbosa MLC, et al. Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorg Med Chem 2010;18:5007-15
64. France CP, Winger G, Medzihradsky F, et al. Mirfentanil - pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J Pharm Exp Ther 1991;258:502-10
65. Imase H, Kishida M. Pyridine and pyrazine derivatives as CETP inhibitors, their preparation, pharmaceutical compositions, and use in therapy. WO2008058967; 2008
66. Burns CJ, Harte MF, Palmer JT. Pyrazines derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as kinase inhibitors. WO2008058341; 2008
67. Lee SJ, Kong YD, Jeon MG, et al. Pyrido[2,3-b]pyrazines derivatives as antitumor agents. KR2008004646; 2008
68. Huang KH, Smith ED, Veal J. Pyrimidine and pyrazine derivatives as HSP-90 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of proliferative diseases. WO2008024974; 2008
69. Muci A, Finer JT, Lu P, et al. Preparation of imidazo[4,5-b]pyrazine derivatives as modulator of skeletal muscle myosin. WO2008016669; 2008
70. Lochead A, Saady M, Yaiche P. Preparation of substituted N-oxide pyrazine derivatives for treating diseases caused by abnormal activity of GSK3beta. WO2009156857; 2009
71. Di Fabio R, Gentile G, Pozzan A, et al. Pyrazolo[1,5-a]pyrazines derivatives as antagonists of V1b receptors and their preparation, pharmaceutical compositions and use in the treatment of anxiety and depression. WO2009130232; 2009
72. Thompson AS, Cheng H, Pikul S. Process for preparation of pyrazine derivatives as antiviral agents. WO2009114313; 2009
73. Mitchell SA, Currie KS, Blomgren PA, et al. Preparation of 6-aryl-imidazo[1,2-a] pyrazine derivatives as SYK kinase inhibitors. WO2009102468; 2009
74. Deng B, Yang F, Fan J, et al. Preparation of 5,6,7,8-tetrahydro-imidazo [1,5-a]pyrazine derivatives as dipeptidyl peptidase IV inhibitors. CN101468988; 2009
75. Deng B, Yang F, Wang Y, et al. Preparation of 5,6,7,8-tetrahydro-imidazo [1,5-a] pyrazine derivatives as dipeptidyl peptidase IV inhibitors. CN101417999A; 2009
76. Huang Z, Zhao H. Preparation of 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazine derivatives as dipeptidase IV inhibitors. CN101357921A; 2009
77. Huang Z, Zhao H. Preparation of 1,2,4- triazolo[4,3-a] pyrazine derivatives as dipeptidase inhibitors. CN101357923; 2009
78. Huang Z, Zhao H. Preparation of 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazine derivatives as dipeptidase IV inhibitors. CN101357922; 2009
79. Huang Z, Zhao H. Preparation of 1,2,4- triazolo[4,3-a] pyrazine derivatives as dipeptidase inhibitors. CN101357924 A; 2009
80. Jeong Jae. Uk; Ramanjulu, Joshi M.; Marquis, Robert W.Preparation of pyrazine derivatives as calcium receptor antagonists. WO2009006245A2; 2009
81. Dean DK, Munoz-Muriedas J, Sime M, et al. Preparation of tetrahydro[1,2,4] triazolo[4,3-a]pyrazine derivatives for use as P2X7 modulators. WO2010125102; 2010
82. Dean DK, Munoz-Muriedas J, Sime M, et al. Preparation of 5,6,7,8- tetrahydroimidazo[1,2-a] pyrazine derivatives as P2X7 modulators. WO2010125101;2010
83. Neumann WL, Freskos JN, Dorshow RB. Preparation of pyrazine derivatives for use as optical imaging agents and COX-II inhibitors. WO2010121003; 2010
84. Charrier J-D, Durrant S, Kay D, et al. Pyrazine derivatives useful as inhibitors of ATR kinase and their preparation and use in the treatment of diseases. WO2010071837;2010
85. Hasegawa D, Kitazawa N. Preparation of 2-(imidazol-1-yl)pyrazine derivatives as inhibitors of protein amyloid-beta (Abeta). WO2010098495;2010
86. Chin E, Li J, Talamas FX, Wang B. Pyrazine derivatives as NS5B polymerase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HCV infection. WO2010034671;2010
87. Folmer BJB, De Man APA, Gernette ES, et al. Preparation of thieno [2,3-b] pyrazine derivatives as B-Raf inhibitors for treating cancer. WO2011147764; 2011
88. Bartolome-Nebreda JM, Conde-Ceide S, MacDonald GJ, et al. Preparation of imidazo[1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases. WO2011110545; 2011
89. Feng T, Sanganee HJ, Wada H. Preparation of pyrazine derivatives useful in the treatment of bone-related disorders or conditions. WO2011089416;2011
90. Bhalay G, Edwards L, Howsham C, et al. Preparation of pyrazine derivatives as epithelial sodium channel blockers. WO2012035158; 2012
91. Wang Y, Sun Y, Yu P, et al. Pyrazine derivatives, process for manufacture and use thereof in the treatment and prevention of diseases. WO 2012003784; 2012; 92
92. Rajagopalan R, Neumann WL, Poreddy AR, et al. Hydrophilic pyrazine dyes as exogenous fluorescent tracer agents for the real-time-point-of-care measurement of glomerular filtration rate. J Med Chem 2011;54:5048-58
93. Rajagopalan R, Dorshow RB, Neumann WL. Pyrazine derivavtives and uses thereof in renal function monitoring. US8115000; 2012